These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34152660)

  • 1. Chronic stress and Alzheimer's disease.
    Mohammadi S; Zandi M; Dousti Kataj P; Karimi Zandi L
    Biotechnol Appl Biochem; 2022 Aug; 69(4):1451-1458. PubMed ID: 34152660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between stress and Alzheimer's disease.
    Justice NJ
    Neurobiol Stress; 2018 Feb; 8():127-133. PubMed ID: 29888308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic strategy for Parkinson's and Alzheimer's disease.
    Esposito E; Cuzzocrea S
    Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential predictors of hippocampal atrophy in Alzheimer's disease.
    Dhikav V; Anand K
    Drugs Aging; 2011 Jan; 28(1):1-11. PubMed ID: 21174483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease.
    Werner FM; Covenas R
    Curr Pharm Des; 2016; 22(14):2064-71. PubMed ID: 26818863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Pathological Benefits of Edaravone for Alzheimer's Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model.
    Feng T; Yamashita T; Shang J; Shi X; Nakano Y; Morihara R; Tsunoda K; Nomura E; Sasaki R; Tadokoro K; Matsumoto N; Hishikawa N; Ohta Y; Abe K
    J Alzheimers Dis; 2019; 71(1):327-339. PubMed ID: 31403949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of metals in Alzheimer's disease.
    Das N; Raymick J; Sarkar S
    Metab Brain Dis; 2021 Oct; 36(7):1627-1639. PubMed ID: 34313926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease.
    Zang G; Fang L; Chen L; Wang C
    Mol Med Rep; 2018 May; 17(5):7293-7300. PubMed ID: 29568940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders.
    Vandael D; Gounko NV
    Transl Psychiatry; 2019 Oct; 9(1):272. PubMed ID: 31641098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease: cognitive and behavioral pharmacotherapy.
    Cummings JL; Mendez MF
    Conn Med; 1997 Sep; 61(9):543-52. PubMed ID: 9334509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Neuroinflammation on Hippocampal Neurogenesis: Relevance to Aging and Alzheimer's Disease.
    Valero J; Bernardino L; Cardoso FL; Silva AP; Fontes-Ribeiro C; Ambrósio AF; Malva JO
    J Alzheimers Dis; 2017; 60(s1):S161-S168. PubMed ID: 28671124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to β-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment.
    Ostapchenko VG; Chen M; Guzman MS; Xie YF; Lavine N; Fan J; Beraldo FH; Martyn AC; Belrose JC; Mori Y; MacDonald JF; Prado VF; Prado MA; Jackson MF
    J Neurosci; 2015 Nov; 35(45):15157-69. PubMed ID: 26558786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive disability in alzheimer's disease and its management.
    Corsi M; Di Raimo T; Di Lorenzo C; Rapp-Ricciardi M; Archer T; Ricci S; Businaro R
    Clin Ter; 2016; 167(5):e123-e126. PubMed ID: 27845490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease.
    Jiang T; Sun Q; Chen S
    Prog Neurobiol; 2016 Dec; 147():1-19. PubMed ID: 27769868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's associated inflammation, potential drug targets and future therapies.
    Stuchbury G; Münch G
    J Neural Transm (Vienna); 2005 Mar; 112(3):429-53. PubMed ID: 15723159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets.
    Caraci F; Copani A; Nicoletti F; Drago F
    Eur J Pharmacol; 2010 Jan; 626(1):64-71. PubMed ID: 19837057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oxidative stress in the pathogenesis of Alzheimer's disease.
    Filipcik P; Cente M; Ferencik M; Hulin I; Novak M
    Bratisl Lek Listy; 2006; 107(9-10):384-94. PubMed ID: 17262991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer's Disease.
    Chakraborty S; ThimmaReddygari J; Selvaraj D
    Comb Chem High Throughput Screen; 2021; 24(7):1083-1092. PubMed ID: 32875981
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.